Hyperlipidemia. Hyperlipidemia, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Herbal softgel containing hydroalcoholic extract of garlic (Allium sativum) 47.4 mg, cranberry (Vaccinium myrtillus) 20.4 mg, ginger (Zingiber officinale) 14.8 mg,
Sponsors
Gol darou Company
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Age 18 to 60 years Participants with total cholesterol of 200 mg/dL and over Participants with triglyceride 150 mg/dL and over Participants with low density lipoprotein cholesterol from 130 to less than 190 mg/dL Body mass index below 30 kg/m2
Exclusion criteria
Exclusion criteria: Use of alcohol and/or other substances of abuse Diseases affecting serum lipids (e.g., diabetes, thyroid disorders, and pancreatitis). Use of medications or supplements affecting serum lipids (e.g., statins, fibrates, estrogens, progestins, beta-blockers, thiazide diuretics, and fish oil) in the past 2 months Liver or kidney disease Pregnancy Lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total cholesterol (TC). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: All venous blood samples were taken in the morning between 7:00 AM and 9:00 AM after a 12-hour fast, and the blood samples were stored at -70°C until biochemical analysis. This test was performed in the laboratory of the Cardiovascular Research Institute using the enzymatic method and a Hitachi autoanalyzer (manufactured by Eppendorf, Germany) and kits from Pars Ozmon.;Triglyceride (TG). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: All venous blood samples were taken in the morning between 7:00 AM and 9:00 AM after a 12-hour fast, and the blood samples were stored at -70°C until biochemical analysis. This test was performed in the laboratory of the Cardiovascular Research Institute using the enzymatic method and a Hitachi autoanalyzer (manufactured by Eppendorf, Germany) and kits from Pars Ozmon.;Low density lipoprotein cholesterol (LDL-C). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: All venous blood samples were taken in the morning between 7:00 AM and 9:00 AM after a 12-hour fast, and the blood samples were stored at -70°C until biochemical analysis. This test was performed in the laboratory of the Cardiovascular Research Institute using the enzymatic method and a Hitachi autoanalyzer (manufactured by Eppendorf, Germany) and kits from Pars Ozmon.;High density lipoprotein cholesterol (HDL-C). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: All venous blood samples were taken in the morning between 7:00 AM and 9:00 AM after a 12-hour fast, and the blood samples were stored at -70°C until biochemical analysis. This test was performed in the laboratory of the Cardiovascular Research Institute using the enzymatic method and a Hitachi autoanalyzer (manufactured by Eppendorf, Germany) and kits from Pars Ozmon | — |
Secondary
| Measure | Time frame |
|---|---|
| Apoprotein A (Apo A). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Apo A was measured using a modified immunotubercular method and according to the instructions of the commercial kit DiaSys, Germany.;Apoprotein B (Apo B). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Apo A was measured using a modified immunotubercular method and according to the instructions of the commercial kit DiaSys, Germany.;High sensitive-C reactive protein (hs-CRP). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Immunotubercular method using Pars Azmoun kits.;Erythrocyte sedimentation rate (ESR). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Immunotubercular method using Pars Azmoun kits.;Fibrinogen. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Thrombin-mediated clotting.;Interleukin 6 (IL6). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Colorimetry, using commercial ELISA kits (Bioassay Technology Laboratory, Shanghai, China; E1239Hu) and according to the kit instructions by ELISA machine.;Oxidized-low density lipoprotein cholesterol (OX-LDL-C). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Colorimetry, using commercial ELISA kits (Bioassay Technology Laboratory, Shanghai, China; E1239Hu) and according to the kit instructions by ELISA machine.;Malondialdehyde (MDA). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Colorimetry, using commercial ELISA kits (Bioassay Technology Laboratory, Shanghai, China; E1239Hu) and according to the kit instructions by ELISA machine.;Total antioxidant capacity (TAC). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Colorimetry, u | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNoushin Mohammadifard
Esfahan University of Medical Sciences
Outcome results
None listed